Nkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer
September 18, 2019 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Appoints Vice President of Regulatory Affairs
September 10, 2019 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials
September 04, 2019 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Presents Data at AACR Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity of NK Cells
April 01, 2019 16:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing engineered Natural Killer (NK) cell therapies to fight cancer,...
Nkarta Therapeutics Announces Appointment of Matthew Plunkett, Ph.D., as Chief Financial Officer
December 10, 2018 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing engineered Natural Killer (NK) immune cells to fight cancer,...
Nkarta Therapeutics Appoints Kanya Rajangam, M.D., Ph.D, as Chief Medical Officer
November 27, 2018 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
November 09, 2018 08:00 ET
|
Nkarta
NK cell potency and persistence significantly improved using cell engineering technology60% increase in cytotoxicity observed with Nkarta NK cells relative to control NK cellsSingle in vivo...
Nkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters
July 09, 2018 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital
June 11, 2018 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
Nkarta Therapeutics Appoints Veteran Executive Paul Hastings as CEO to Lead Next Phase of Growth
March 01, 2018 14:05 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing natural killer (NK) immune cells to fight cancer, announced that...